Research Article: Sclerostin and OPG/RANK-L system take part in bone remodeling in patients with acromegaly
Abstract:
Introduction: Acromegaly is a disease characterized by enhanced bone turnover with persistently high vertebral fracture risk. Sclerostin is a glycoprotein, which acts as an inhibitor of bone formation and activates osteoclast-mediated bone resorption. The osteoprotegerin (OPG)/receptor activator for the nuclear factor ? B ligand (RANK-L) system is crucial for controlling bone metabolism.
Introduction:
Objective: The study aimed primarily at evaluating sclerostin, OPG, and RANK-L concentrations in patients at different stages of acromegaly activity. The secondary aim was to identify an association of sclerostin with the OPG/RANK-L system and bone mineral density (BMD).
Read more